BDF Gestion Sells 2,964 Shares of Danaher Corporation $DHR

BDF Gestion lessened its holdings in Danaher Corporation (NYSE:DHRFree Report) by 17.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,251 shares of the conglomerate’s stock after selling 2,964 shares during the quarter. BDF Gestion’s holdings in Danaher were worth $2,825,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. White Pine Capital LLC grew its stake in shares of Danaher by 1.4% in the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after acquiring an additional 49 shares during the last quarter. Boyd Watterson Asset Management LLC OH boosted its stake in Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after purchasing an additional 51 shares in the last quarter. Worth Financial Advisory Group LLC grew its position in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares during the last quarter. Bruce G. Allen Investments LLC increased its stake in Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after purchasing an additional 54 shares in the last quarter. Finally, Texas Bank & Trust Co raised its holdings in Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after buying an additional 55 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.2%

Danaher stock opened at $224.78 on Friday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a market cap of $158.77 billion, a P/E ratio of 46.35, a P/E/G ratio of 4.35 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The business has a 50-day simple moving average of $220.37 and a two-hundred day simple moving average of $206.91.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the firm posted $1.71 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. Analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Analysts Set New Price Targets

Several brokerages recently weighed in on DHR. KeyCorp reissued an “overweight” rating on shares of Danaher in a research report on Thursday. TD Cowen increased their target price on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. HSBC boosted their price target on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Jefferies Financial Group increased their price objective on Danaher from $245.00 to $255.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Bank of America reduced their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $248.25.

View Our Latest Analysis on DHR

Insider Activity at Danaher

In other news, Director Teri List sold 3,298 shares of Danaher stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Read More

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.